Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials

BACKGROUND: Gliflozins altering the sodium-glucose transport protein 2 (SGLT2) in the nephron, represent alone or in combination a promising treatment option for patients with type II diabetes mellitus. In addition to glucose control, these drugs provide benefits including reduced risk of long-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Tornyos, Dániel, Meuer, Maximilian, Lukács, Réka, El Alaoui El Abdallaoui, Oumaima, Kupó, Péter, Faludi, Réka, Komócsi, András
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760750/
https://www.ncbi.nlm.nih.gov/pubmed/36545024
http://dx.doi.org/10.3389/fcvm.2022.1041200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760750/
https://www.ncbi.nlm.nih.gov/pubmed/36545024
http://dx.doi.org/10.3389/fcvm.2022.1041200

Ejemplares similares